Antibody Response After Single H1N1 Influenza Vaccine in Chronic Dialysis Patients

Authors


  • Presented in part at the XLVIII ERA-EDTA Congress held June 23–26, 2011 in Prague, Czech Republic.

Dr Alper Azak, MD, Department of Nephrology, Ankara Education and Research Hospital, Ankara 06000, Turkey. Email: dralperazak@gmail.com

Abstract

The first influenza pandemic of this century happened through a rapid spread of a novel swine-derived H1N1 influenza virus. Vaccines are produced in order to avoid the infection. Children and other high risk groups are highly recommended for vaccination due to the high probability of contracting the virus. Chronic kidney disease patients were also accepted as a risk group and vaccination of all patients undergoing hemodialysis or peritoneal dialysis was recommended. The results of H1N1 influenza virus vaccine on patients receiving hemodialysis and peritoneal dialysis are analyzed. Antibody titers of both hemodialysis and peritoneal dialysis patients were elevated after vaccination. Peritoneal dialysis patients responded better.

Ancillary